公开(公告)号：WO2023006565A1

公开(公告)日：2023-02-02

申请号：PCT/EP2022/070466

申请日：2022-07-21

Applicant: MEDICHEM, S.A.

Inventor： LOZANO VELILLA, José Andrés ,  GARCÍA ROVIRA, Montserrat ,  DURAN LÓPEZ, Ernesto

IPC: A61K9/00 ,  A61K47/02 ,  A61K47/18 ,  A61K31/4152

Abstract: This invention relates to a process for preparing a formulation of edaravone or a pharmaceutically acceptable salt thereof, concretely an aqueous injectable formulation, which contains low amounts of a certain impurity. This process comprises heat-sterilization of an aqueous formulation of edaravone or pharmaceutically acceptable salt thereof, which comprises bisulfite anions (HSO3-) and contains less than 1 ppm of oxygen.

公开(公告)号：WO2020025579A1

公开(公告)日：2020-02-06

申请号：PCT/EP2019/070433

申请日：2019-07-30

Applicant: MEDICHEM, S.A.

Inventor： CASADEVALL PUJALS, Gemma ,  GARCIA ROVIRA, Montserrat

IPC: A61K9/00 ,  A61K9/50 ,  A61K31/00 ,  A61K31/554 ,  A61P25/18

Abstract: The present invention relates to oral pharmaceutical compositions comprising quetiapine fumarate which comprise coated discrete units. The composition of the invention is chemically and physically stable, has a good in vitro dissolution rate thereby showing good bioavailability and resulting bioequivalent to marketed Seroquel® tablets.

公开(公告)号：WO2012035057A2

公开(公告)日：2012-03-22

申请号：PCT/EP2011/065925

申请日：2011-09-14

Applicant: MEDICHEM S.A. ,  MANGION, Bernardino ,  DURÁN LÓPEZ, Ernesto

Inventor： MANGION, Bernardino ,  DURÁN LÓPEZ, Ernesto

IPC: C07D413/14

CPC classification number: C07D413/14 ,  G01N33/15

Abstract: The present invention relates to a process for determining the suitability for distribution of a batch of rivaroxaban or of a pharmaceutical composition thereof. In particular, it also relates to two impurities of rivaroxaban, to their use as reference markers to determine the purity of a sample of rivaroxaban or a composition thereof, to analytical methods for determining the purity of a sample of rivaroxaban or a composition thereof and to a process of preparing rivaroxaban or pharmaceutical compositions thereof which are free or substantially free of such impurities.

Abstract translation: 本发明涉及一种确定一批利伐沙班或其药物组合物分布的适合性的方法。 特别是，它还涉及利伐沙班的两种杂质，它们用作参考标记以确定利伐沙班样品或其组合物的纯度，用于确定利伐沙班样品或其组合物的纯度的分析方法，以及 制备不含或基本上不含这些杂质的利伐沙班或其药物组合物的方法。

公开(公告)号：WO2010115906A1

公开(公告)日：2010-10-14

申请号：PCT/EP2010/054555

申请日：2010-04-06

Applicant: MEDICHEM, S.A. ,  GAVALDÁ ESCUDÉ, Ana

Inventor： GAVALDÁ ESCUDÉ, Ana

IPC: C07C237/18 ,  C07C231/12

CPC classification number: C07C237/18 ,  C07C231/12 ,  Y02P20/55

Abstract: The invention relates to 2-{2-amino-3-[hydroxy(phenyl)methyl]phenyl} acetamide, a process for its preparation, and its use as a reference marker and reference standard for analyzing the purity of nepafenac.

Abstract translation: 本发明涉及2- {2-氨基-3- [羟基（苯基）甲基]苯基}乙酰胺，其制备方法及其用作参考标记和用于分析奈帕芬尼的纯度的参考标准。

公开(公告)号：WO2010041134A1

公开(公告)日：2010-04-15

申请号：PCT/IB2009/007080

申请日：2009-10-09

Applicant: MEDICHEM, S.A. ,  MANGION, Bernardino

Inventor： MANGION, Bernardino

IPC: C07D403/06

CPC classification number: C07D403/06

Abstract: Disclosed is a process for preparing the malic acid salt of sunitinib comprising reacting malic acid with an acid addition salt of sunitinib, which is a cancer treatment agent, wherein the acid addition salt of sunitinib is an acid weaker than malic acid. Also disclosed are acid addition salts of sunitinib wherein the acid is an acid weaker than malic acid.

Abstract translation: 公开了一种制备舒尼替尼的苹果酸盐的方法，其包括使苹果酸与作为癌症治疗剂的舒尼替尼的酸加成盐反应，其中舒尼替尼的酸加成酸是比苹果酸弱的酸。 还公开了舒尼替尼的酸加成盐，其中酸是比苹果酸弱的酸。

公开(公告)号：WO2009156837A2

公开(公告)日：2009-12-30

申请号：PCT/IB2009/006056

申请日：2009-06-26

Applicant: MEDICHEM, S.A. ,  WINTER, Stephen Benedict David ,  BENITO VELEZ, Monica

Inventor： WINTER, Stephen Benedict David ,  BENITO VELEZ, Monica

IPC: C07D403/06 ,  A61K31/404

CPC classification number: C07D403/06 ,  A61K31/404

Abstract: Disclosed are new forms of the anticancer agent sunitinib of formula (I), and pharmaceutically acceptable salts thereof, including amorphous form sunitinib malate and sunitinib malate Form III. Also disclosed is a process for preparing and pharmaceutical compositions comprising amorphous form sunitinib malate.

Abstract translation: 公开了式（I）的抗癌剂舒尼替尼和其药学上可接受的盐的新形式，包括无定形形式的苹果酸舒尼替尼和苹果酸舒尼替尼。 还公开了一种制备包含无定形形式的苹果酸舒尼替尼的药物组合物的方法。

公开(公告)号：WO2009153651A1

公开(公告)日：2009-12-23

申请号：PCT/IB2009/005994

申请日：2009-06-19

Applicant: MEDICHEM, S.A. ,  CHAMORRO GUTIÉRREZ, Iolanda ,  XIFRA GARCIA, Raül

Inventor： CHAMORRO GUTIÉRREZ, Iolanda ,  XIFRA GARCIA, Raül

IPC: C07D295/14

CPC classification number: C07D295/14

Abstract: Disclosed is a process for preparing purified ranolazine of formula (I), which is indicated for the chronic treatment of angina, comprising reacting l-[(2,6- dimethylphenyl)aminocarbonyl]piperazine with l-phenoxy-2,3-epoxypropane in an inert solvent followed by precipitating the ranolazine.

Abstract translation: 公开了制备用于慢性治疗心绞痛的式（I）的精氨酸拉诺嗪的方法，其包括使1 - [（2,6-二甲基苯基）氨基羰基]哌嗪与1-苯氧基-2,3-环氧丙烷反应 惰性溶剂，然后沉淀雷诺嗪。

公开(公告)号：WO2009118657A8

公开(公告)日：2009-10-01

申请号：PCT/IB2009/005506

申请日：2009-03-27

Applicant: MEDICHEM, S.A. ,  WINTER, Stephen, Benedict, David ,  BURGAROLAS MONTERO, Maria, Carmen

Inventor： WINTER, Stephen, Benedict, David ,  BURGAROLAS MONTERO, Maria, Carmen

IPC: C07C211/42 ,  C07C309/04 ,  A61P25/16 ,  A61K31/135

Abstract: The invention relates to a polymorphic form of rasagiline mesylate, and to processes for preparing the same.

公开(公告)号：WO2009068967A1

公开(公告)日：2009-06-04

申请号：PCT/IB2008/003232

申请日：2008-11-25

Applicant: MEDICHEM, S.A. ,  BERNARDINO, Mangion

Inventor： BERNARDINO, Mangion

IPC: C07C227/04 ,  C07C229/08 ,  A61K31/195 ,  A61P29/00

CPC classification number: C07C227/04 ,  C07C229/08

Abstract: The present invention is related to processes suitable for industrial synthesis of pregabalin from (i?)-(-)-3-(carbamoylmethyl)-5-methylhexanoic using sodium hypochlorite as described herein. In addition, the present invention is related to pregabalin which is substantially free of impurities and pharmaceutical compositions comprising pregabalin.

Abstract translation: 本发明涉及适用于使用本文所述的次氯酸钠从（R） - （ - ） - 3-（氨基甲酰基甲基）-5-甲基己酸工业合成普瑞巴林的方法。 此外，本发明涉及基本上不含杂质的普瑞巴林和包含普瑞巴林的药物组合物。

公开(公告)号：WO2008117123A3

公开(公告)日：2008-10-02

申请号：PCT/IB2007/004566

申请日：2007-10-16

Applicant: MEDICHEM, S.A. ,  SOLDEVILLA MADRID, Nuria

Inventor： SOLDEVILLA MADRID, Nuria

IPC: C07D211/32

Abstract: The invention relates to improved methods for preparing polymorph Form I of 2,3- dihydro-5,6-dimethoxy-2-[[ 1 -(phenylmethy l)-4-piperidinyl]methyl- 1 H -inden- 1 -one hydrochloride (i.e., donepezil hydrochloride).

Abstract translation: 本发明涉及制备2,3-二氢-5,6-二甲氧基-2 - [[1-（苯基甲基）-4-哌啶基]甲基-1 H-茚-1-酮盐酸盐（即盐酸多奈哌齐）。